Small Molecule Compounds Modulate Akt Signaling for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's lack effective therapies to delay disease progression, with existing research indicating that inadequate Akt activity and excessive GSK-3β activity contribute to tau protein hyper-phosphorylation and neuronal death, and there is a need for non-toxic drugs that can protect and promote the survival of neurons.
Innovation Solution
Administration of specific compounds that reduce GSK-3β activity and increase acetylation of neuronal histones, thereby enhancing Akt signaling and reducing tau phosphorylation, which can be achieved through the use of compounds with specific structural formulas that contact neural cells to modulate the activity of GSK-3β and increase the phosphorylation of Akt.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Akt signaling is increased to protect neurons, then neuronal survival is improved, but the mechanism and method to achieve this increase is not certain and lacks effective therapy
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to activate Akt signaling. These compounds bind to and inhibit PP2A phosphatase, preventing it from dephosphorylating Akt, thereby maintaining Akt in its active phosphorylated state. This intermediary approach provides a concrete therapeutic mechanism to increase neuronal survival without directly manipulating complex signaling pathways.
Solution Approach 2:
The patent changes the phosphorylation state parameter of Akt by inhibiting PP2A activity. By preventing dephosphorylation of Akt at specific sites (e.g., Ser473), the compounds maintain Akt in a hyperphosphorylated active state, which confers neuroprotection. This parameter change approach transforms the uncertain mechanism into a controllable biochemical parameter.
2Reliability
If GSK-3β activity is reduced to prevent tau hyper-phosphorylation, then tauopathy progression is slowed, but specific non-toxic drugs to achieve this are needed
Solution Approach 1:
The patent employs small molecule compounds as intermediaries that indirectly reduce GSK-3β activity by activating Akt. Rather than directly inhibiting GSK-3β with potentially toxic compounds, the approach uses PP2A inhibition as a mediator to upstream activate Akt, which then phosphorylates and inhibits GSK-3β. This indirect mechanism reduces toxicity while achieving the desired effect of preventing tau hyper-phosphorylation.
Solution Approach 2:
The patent applies preliminary action by activating Akt before GSK-3β can cause significant tau hyper-phosphorylation. By pre-activating the protective signaling pathway through PP2A inhibition, the system establishes a protective state that prevents subsequent tau pathology progression, rather than attempting to reverse established damage.
3Ease of operation
If existing therapies are used for neurodegenerative diseases, then current treatment protocols are maintained, but no therapy is known to delay disease progression
Solution Approach 1:
The patent introduces small molecule compounds as pharmacological intermediaries to bridge the gap between current symptomatic treatments and the desired outcome of disease modification. These compounds serve as mediators that activate endogenous protective pathways (Akt signaling) to slow disease progression, while maintaining operational simplicity through oral administration and standard dosing regimens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds effectively induce phosphorylated Akt, increase acetylation of histones, and reduce tau phosphorylation, offering neuroprotective effects and potential therapeutic benefits for neurodegenerative diseases by inhibiting the progression of tauopathies.
Implementation Method 1
The compounds increase the phosphorylation of a regulatory protein Akt
Implementation Method 2
The compounds increase the acetylation of histone proteins in neural cells
Implementation Method 3
GSK-3β itself is regulated by other serine-threonine kinases especially Akt
Data Source
AI summary
Disclosed herein are methods of treating neurodegenerative diseases comprising administering to the subject a compound having the structure:wherein α and R1-R8 are described herein, or a compound having the structure:wherein Y, Z, and R21, R24, R25, and R31-R33 are described herein.